Blog
About

3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Although p16 protein expression, a surrogate marker of oncogenic human papillomavirus (HPV) infection, is recognized as a prognostic marker in oropharyngeal squamous cell carcinoma (OPSCC), its prevalence and significance have not been well established in cancer of the oral cavity, hypopharynx, or larynx, collectively referred as non-OPSCC, where HPV infection is less common than in the oropharynx.

          Related collections

          Author and article information

          Journal
          J. Clin. Oncol.
          Journal of clinical oncology : official journal of the American Society of Clinical Oncology
          1527-7755
          0732-183X
          Dec 10 2014
          : 32
          : 35
          Affiliations
          [1 ] Christine H. Chung and Elana J. Fertig, Johns Hopkins University, Baltimore, MD; Qiang Zhang and Jonathan Harris, Radiation Therapy Oncology Group Statistical Center, Philadelphia, PA; Christina S. Kong and Quynh-Thu Le, Stanford University, Stanford; Richard C. Jordan, University of California at San Francisco, San Francisco, CA; Paul M. Harari, University of Wisconsin Carbone Cancer Center, Madison; Dian Wang, Medical College of Wisconsin, Milwaukee, WI; Kevin P. Redmond, University of Cincinnati, Cincinnati; Maura L. Gillison, Ohio State University, Columbus, OH; George Shenouda, McGill University Health Centre, Montreal, Quebec, Canada; Andy Trotti, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; and David Raben, University of Colorado, Denver, CO. cchung11@jhmi.edu.
          [2 ] Christine H. Chung and Elana J. Fertig, Johns Hopkins University, Baltimore, MD; Qiang Zhang and Jonathan Harris, Radiation Therapy Oncology Group Statistical Center, Philadelphia, PA; Christina S. Kong and Quynh-Thu Le, Stanford University, Stanford; Richard C. Jordan, University of California at San Francisco, San Francisco, CA; Paul M. Harari, University of Wisconsin Carbone Cancer Center, Madison; Dian Wang, Medical College of Wisconsin, Milwaukee, WI; Kevin P. Redmond, University of Cincinnati, Cincinnati; Maura L. Gillison, Ohio State University, Columbus, OH; George Shenouda, McGill University Health Centre, Montreal, Quebec, Canada; Andy Trotti, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; and David Raben, University of Colorado, Denver, CO.
          Article
          JCO.2013.54.5228
          10.1200/JCO.2013.54.5228
          25267748
          © 2014 by American Society of Clinical Oncology.

          Comments

          Comment on this article